rAd-p53 enhances the sensitivity of human gastric cancer cells to chemotherapy

Table 5 Apoptotic rate in gastric cancer cells 48 h after treatment with rAd-p53, oxaliplatin or rAd-p53 plus oxaliplatin

Treatment	Gastric cancer cell line
	rAd-p53 (vp/mL)	OXA (μg/mL)	SGC-7901	BGC-823	HGC-27
OXA	0	3.2	33.52 ± 1.6ea	23.28 ± 1.35ea	18.72 ± 1.61ea
rAd-p53	5 × 106	0	7.89 ± 1.13ca	6.51 ± 0.97ca	4.07 ± 0.83ca
	5 × 107	0	12.47 ± 1.43ca	8.78 ± 1.34ca	6.43 ± 0.79ca
	5 × 108	0	21.84 ± 1.05ca	14.24 ± 0.89ca	11.72 ± 1.12ca
	5 × 109	0	36.73 ± 1.03ca	28.64 ± 1.75ca	21.82 ± 1.81ca
rAd-p53 + OXA	5 × 106	3.2	42.38 ± 1.51eca	35.72 ± 1.13eca	28.84 ± 1.21eca
	5 × 107	3.2	54.84 ± 1.26eca	48.63 ± 1.62eca	34.51 ± 1.47eca
	5 × 108	3.2	58.41 ± 1.13eca	51.71 ± 1.41eca	38.5 ± 1.16eca
	5 × 109	3.2	63.91 ± 1.23eca	55.73 ± 1.35eca	42.92 ± 1.33eca
Control	0	0	4.67 ± 1.32	1.74 ± 0.67	1.15 ± 0.58

^aP < 0.05 vs control;

^cP < 0.05, rAd-p53 vs rAd-p53 + oxaliplatin (OXA) with the same dose of rAd-p53;

^eP < 0.05, OXA vs rAd-p53 + OXA at the same dose of OXA.